The combination of these two drugs inhibited the cell viability of EGFR-overexpressing NSCLC cells, which was not evident in the double-mutant EGFR 1975 cell line, clearly suggesting a synergistic effect of theasinensin A and nimotuzumab in EGFR-expressing NSCLCs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.